Format

Send to

Choose Destination
Anticancer Res. 2015 Jul;35(7):4207-14.

Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations.

Author information

1
Department of Oncology, National Taiwan University, Hsin-Chu Branch, Hsinchu, Taiwan, R.O.C. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
2
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
3
Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
4
Division of Colorectal Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
5
Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
6
Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
7
Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
8
Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
9
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
10
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C. khyeh@ntu.edu.tw.

Abstract

BACKGROUND:

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear.

PATIENTS AND METHODS:

This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011.

RESULTS:

The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC.

CONCLUSION:

Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12.

KEYWORDS:

Cetuximab; KRAS; epidermal growth factor receptor; metastatic colorectal cancer

PMID:
26124380
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center